Filip Janku, MD, PhD, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma.
Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma. Researchers concluded that this combination of agents was well tolerated and demonstrated encouraging activity.
<<<
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More